Aviceda Therapeutics
Aviceda Therapeutics: A late-stage biotech firm developing glyco-immune disease drugs, with a focus on eye diseases, fibrosis, neurology, and oncology.
Founded
2018Aviceda Therapeutics: A late-stage biotech firm developing glyco-immune disease drugs, with a focus on eye diseases, fibrosis, neurology, and oncology.
Founded with a mission to revolutionize the treatment of glyco-immune diseases, Aviceda Therapeutics is a late-stage, pre-clinical biotech company. The organization leverages the power of glycobiology to create next-generation immunomodulators aimed at addressing chronic non-resolving inflammation and the innate immune system. Aviceda’s product pipeline includes treatments for eye diseases, fibrosis, neurology, and oncology, utilizing highly selective ligands for maximum specificity towards target immune cells and diseases.
Aviceda Therapeutics boasts a team of notable experts in biotechnology and immunology, alongside significant backing from prominent investors in the biotech sector. The company has achieved key milestones in pre-clinical development, positioning itself as a leader in glyco-therapeutics. Through its innovative approach and cutting-edge technologies, Aviceda aims to make a profound impact on the treatment landscape for chronic inflammatory and immune-related conditions.
Companies similar to Aviceda Therapeutics include Abvc Biopharma, Avidity Biosciences, Avexegen Therapeutics and Invea Therapeutics.
Aviceda Therapeutics was founded in 2018.
Aviceda Therapeutics' most recent funding round was for $15.6M (USD) in May 2023.
As of May 19, 2023, Aviceda Therapeutics has raised a total of $69.3M (USD).
Aviceda Therapeutics has 17 employees as of Feb 5, 2024.
Avexegen Therapeutics
